35370-93-5 Usage
Molecular weight
184.24 g/mol
Structure
The compound consists of a thioamide group (-CONH2) attached to a fluorophenoxyethyl moiety (-C2H4-O-C6H4-F).
Appearance
It is a pale yellow solid.
Solubility
It is soluble in common organic solvents such as ethanol, methanol, and acetonitrile.
Stability
It is stable under normal temperature and pressure, but may decompose upon exposure to heat, light, or oxidizing agents.
Reactivity
The compound can undergo various chemical reactions, such as acylation, alkylation, and arylation, due to the presence of the thioamide group.
Biological activity
The compound has potential biological activities, which are yet to be fully explored, that may make it a potential drug candidate for the treatment of various diseases and conditions.
Synthesis
The compound can be synthesized through various methods, such as the reaction of a fluorophenol with an ethanethioamide group.
Use
It is commonly used in organic synthesis and pharmaceutical research as a starting material for various reactions and as a potential drug candidate.
Safety
It should be handled with care and proper safety measures should be taken while working with this compound as it may have potential hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 35370-93-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,3,7 and 0 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 35370-93:
(7*3)+(6*5)+(5*3)+(4*7)+(3*0)+(2*9)+(1*3)=115
115 % 10 = 5
So 35370-93-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H8FNOS/c9-6-1-3-7(4-2-6)11-5-8(10)12/h1-4H,5H2,(H2,10,12)
35370-93-5Relevant articles and documents
Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors
Du, Chenxi,Du, Kui,Feng, Chengjie,Lv, Weiping,Shen, Runpu,Sun, Haopeng,Xi, Meiyang
supporting information, (2022/02/14)
Butyrylcholinesterase (BuChE) is recently regarded as a biomarker in progressed Alzheimer's disease (AD). Development of selective BuChE inhibitors has attracted a great deal of interest and may be a viable therapeutic strategy for AD. Recently, we reported the N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide (1) as a selective BuChE inhibitor. Subsequently, 33 analogs were synthesized and assessed by AChE/BuChE activities, indicating an optimal compound 23. Further kinetic tests suggested a competitive manner. Molecular docking and Molecular dynamics (MD) simulation showed that it interacted with several residues in active site gorge of BuChE, possibly contributing to its selectivity and competitive pattern. Moreover, it showed low cytotoxicity and high blood brain barrier (BBB) permeability. Taken together, 23 was a promising BuChE inhibitor for the treatment of AD.
